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Hypothesis
CascadeAlzheimer's disease (AD) is a progressive chronic disorder and is characterized by β-amyloid plaques and
angiopathy, tau pathology, neuronal cell death, and inﬂammatory responses. The reasons for this disease are
not known. This review proposes the hypothesis that a chronic mild longlasting cerebrovascular dysfunction
could initiate a cascade of events leading to AD. It is suggested that (vascular) risk factors (e.g.
hypercholesterolemia, type 2 diabetes, hyperhomocysteinemia) causes either damage of the cerebrovascular
system including silent strokes or causes dysregulation of beta-amyloid clearance at the blood-brain barrier
resulting in increased brain beta-amyloid. A cascade of subsequent downstream events may lead to disturbed
metabolic changes, and neuroinﬂammation and tau pathology. The role of NGF on the cell death of cholinergic
neurons is discussed. Additional risk factors (e.g. acidosis, metals) contribute to plaque development.5, A-6020 Innsbruck, Austria.
-NC-ND license.© 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Alzheimers disease and other forms of dementia
Sporadic Alzheimer's disease (AD) is a progressive chronic
neurodegenerative disorder (at least 95% of all cases are non-genetic),
and is characterized by severe beta-amyloid deposition (senile
plaques and vascular angiopathy), tau-pathology, cell death of
cholinergic neurons, microglial activation and inﬂammation. AD is
the most aggressive form of dementia and is distinguished from other
forms of dementia. The differentiation of vascular dementia (vaD)
from AD has been based on evidence of a cerebrovascular disorder
(Roth, 1955). However, pure cases of vaD without neurodegenerative
changes are very rare and autopsy of cases clinically diagnosed as vaD
showed that they had pathological signs for AD (Sadowski et al.,
2004). In addition, mild cognitive impairment (MCI) has been deﬁned as
the earliest form of dementia, which partly converts into AD (approx. 15%
to 30% per year). Two additional forms of degenerative non-reversible
forms of dementia have been described, Lewy Body dementia and
frontotemporal dementia,whichcanbedistinguished fromADandvaD. In
addition, other non-speciﬁc forms of dementia are seen during, for
example, HIV, Parkinson's disease, or alcohol-related diseases. Among all
forms of dementia, AD is the most frequent pathological ﬁnding (approx.
60%), followed by vaD (approx. 15%), Lewy body dementia (approx. 15%),
frontotemporal dementia (approx. 5%), and other degenerative forms of
dementia (Gearing et al., 1995; Heinemann and Zerr, 2007). In addition,
the term vascular cognitive impairment (VCI) is used to describeindividuals with signiﬁcant cognitive impairments produced by cerebro-
vascular disease (CVD) (Barone et al., 2009).
2. Cerebrovascular abnormalities in AD
Possibly the most important changes arguing for a vascular
hypothesis in AD are the cerebral bloodﬂow (CBF) measurements in
MCI and the ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) studies measuring glucose uptake. FDG-PET has shown
decreased glucose metabolism in the medial temporal and parietal
lobes of those with the APOE4 gene many decades prior to the typical
age of AD onset, and that AD can be prognosed in cognitively intact
persons showing reduced glucose uptake (Mosconi et al., 2010). In
addition, arterial spin labeling (Alsop et al., 2010), SPECT (Varma et al.,
2002) or H(2)15O positron emission tomography (Ishii et al., 2000)
provided a reﬂection of CBF activity in cognitively intact people who
later converted to AD.
A number of cerebrovascular abnormalities have been described in
AD brains: decreased microvascular density, basement membrane
thickening, endothelial and pericyte damage, diminished glucose
transport across the blood-brain barrier (BBB), vessels that express
inﬂammatory markers, perivascular ﬁbrosis, capillaries with fewer
branches, atrophic vessels, changes in vessel diameter, accumulation
of e.g. collagen, atheriosclerotic plaques, cerebral amyloid angiopathy,
microglial activation in degenerating endothelial cells or thrombotic
lesions (Farkas and Luiten, 2001). It is very difﬁcult to say if these
changes are an initial cause for development of AD or if these changes
occur in late stages of the disease. Anyhow, there is clear evidence that
these cerebrovascular abnormalities result in dysfunctional inﬂux of
toxic compounds into the brain or result in enhanced storage or
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dysregulated oxygen or glucose supply or last not least in a
dsyfunctional clearance of different compounds at the BBB.3. Risk factors for AD and vaD
It is well known that less than 2.5% of all AD cases have a genetic
origin, but themajority of AD is a sporadic form and themajor risk factor
is age (N60 years). The causes for this sporadic AD are yet unknown, but
several risk factorsmay trigger this disease. There is increasing evidence
that vascular risk factors contribute to the pathogenesis of AD (Kudo et
al., 2000; de la Torre and Mussivand, 1993; De la Torre and Stefano,
2000; De la Torre, 2002; Iadecola, 2004; Zlokovic, 2005; Humpel and
Marksteiner, 2005). In fact, a cerebrovascular hypoperfusion caused by
decreased cerebral blood ﬂow, lowered metabolic rates of glucose and
oxygen could be one of the initial events in AD (Breteler, 2000; Dede
et al., 2007; Deschaintre et al., 2009; Farkas and Luiten, 2001; Iadecola,
2004). AD and vaDmay share common risk factors, which indicate that
their pathogenic mechanism could be related (De la Torre, 2002). It is
hypothesized that neurodegeneration in AD may arise from a chronic
mild cerebrovascular dysregulation caused by continuous exposure to
the risk factors over years (Humpel and Marksteiner, 2005), which
precedes hypoperfusion (De la Torre and Stefano, 2000; Iadecola, 2004).
Evidence comes from epidemiological studies that these risk factors are
(Rocchi et al., 2009; De la Torre, 2002; Zlokovic, 2005; Engelberg, 2004):
old age, atherosclerosis, stroke, diabetes, homocysteine, hypertension,
hyperlipidemia, head injury, transient silent strokes, high serum
viscosity, thrombogenic factors, cardiac disease, the apolipoprotein E4
allele, smoking, alcohol consumption, high cholesterol, fat food, reduced
vitamin B12 uptake, high blood pressure, high ﬁbrinogen levels,
hormonal dysregulation, depression, and others. It is evident that
several of these risk factors are vascular risk factors.3.1. Hyperhomocysteinemia
It is well established that elevated plasma levels of the amino acid
homocysteine increase the risk for atherosclerosis, stroke, myocardial
infarction, and AD (Gallucci et al., 2004; Faraci, 2003; Flicker et al.,
2004; Skurk and Walsh, 2004; Ravaglia et al., 2005; Troen, 2005). It
has been reported that plasma homocysteine levels N15 μM increase
the risk for vaD and AD (Clarke et al., 1998; McIlroy et al., 2002;
Seshadri et al., 2002; Luchsinger et al., 2004). In humans the effective
concentration results from total levels of homocysteine and its
oxidation product disulﬁde homocysteine (Lipton et al., 1997).
Hyperhomocysteinemia induces endothelial damage, mitochondrial
disintegration, swelling of pericytes, basement membrane thickening
and perivascular detachment (Weir and Molloy, 2000; Kim et al.,
2002; Troen, 2005), pathologies are also seen in vaD and AD. The
intracellular effects of homocysteine are very divergent: it induces, for
example, caspase-8 and subsequent apoptosis, it stimulates monocyte
chemoattractant protein-1/interleukin-8 and subsequent inﬂammation,
and it enhances oxidative stress (via activation of different oxidases),
inhibits endothelial nitric oxide synthetase, and generates peroxynitrite
with subsequent cell death (Faraci, 2003; Lee et al., 2004; Skurk and
Walsh, 2004). Furthermore, homocysteine decreases capillary
endothelial nitric oxide synthetase (Faraci, 2003) andglucose transporter
and transiently changes different cell adhesion molecules (Lee et al.,
2004). Homocysteine directly induces cell death of cerebrocortical
neurons involving NMDA (Lipton et al., 1997). Chronic hyperhomocys-
teinemia induced by methionin administration enhanced lipid
peroxidaton and decreased glutathione, suggesting the involvement of
oxidative stress (Baydas et al., 2005). These dysfunctions are
accompanied by cognitive impairment and can be counteracted by the
antioxidant melatonin (Baydas et al., 2005).3.2. Hypercholesterolemia
Cholesterol is increasingly recognized to play a major role in the
pathogenesis of AD (Raffai and Weisgraber, 2003; Wellington, 2004;
Wolozin, 2004). This is based on four lines of investigation: (1) the
lipoprotein ApoE4 coordinates the mobilization and redistribution of
cholesterol in the brain and affects the age of onset, (2) intracellular
cholesterol stimulates γ-secretase and amyloid-precursor-protein
(APP)/β-amyloid processing, (3) cholesterol-lowering drugs (statins)
reduce the prevalence of AD and (4) elevated plasma cholesterol in
midlife is associated with an increased risk for AD. Interestingly,
rabbits fed with a 2% cholesterol diet display an accumulation of
intracellular immunolabeled β-amyloid after 4 to 8 weeks (Sparks
et al., 1994) and hypercholesterolemia accelerates the amyloid
pathology in a transgenic mouse model (Refolo et al., 2000; Shie
et al., 2002). Cholesterol does not pass the BBB and is synthesized
locally in the brain and degraded to 24-hydroxy-cholesterol, which is
transported outside the brain into the bloodstream. Cholesterol
regulates γ-secretase with enhanced processing of β-amyloid(1–42).
It is hypothesized that a breakdown of the BBB causes inﬂux of
cholesterol, with subsequent activation of γ-secretase and enhanced
β-amyloid(1–42) production. These ﬁndings are consistent with the
concept thatAD is a dietary-fat induced phenotype of vascular dementia
and accumulation of beta-amyloid-lipoprotein complexes may be an
ampliﬁer of dietary induced inﬂammation (Takechi et al., 2010).
3.3. Hyperglycemia and insulin depletion
Approximately 40–50% of elderly people have an impaired glucose
metabolismor type 2 diabetes and hyperglycemia is a risk for AD (Kalaria,
2009; Carlsson, 2010; Ott et al., 1999). Inded, PET studies demonstrated a
reduced glucose uptake in AD patients (Erol, 2008). Hyperglycemia has
disruptive effects on the brain and markedly affects cognition and
memory (Brands et al., 2004). Hyperglycemia leads to increased levels of
glucose in thebrain, bywhichexcessglucose is converted into sorbitol and
fructose, which inﬂuences several intracellular cascades. Elevated glucose
is also associated with formation of toxic advanced glycation end (AGE)
products, reactive oxygen species (ROS), or hyperhomocysteinemia.
Hyperglycemia is also associated with both structural and functional
alterations in the cerebral vascular system. Cerebral blood ﬂow has been
reported to be decreased in diabetes and thus increasing risk of “silent
strokes.” Longitudinal studies showed an association between insulin
resistance and AD (Erol, 2008). Insulin regulates the metabolism of
β-amyloid and tau and dysfunctional insulin signaling has been linked
to oxidative stress and mitochondrial dysfunction, resulting in
disturbances of cellular glucose, acetylcholine, cholesterol and ATP levels,
impaired membrane function, accumulation of β-amyloid and tau
hyperphosporylation (Erol, 2008). An interesting in vivo mouse model
shows hyperphosphorylated tau after streptozotocin-induced insulin
deﬁciency (Clodfelder-Miller et al., 2006).
3.4. Chronic alcoholism
Alcohol may be a risk factor for AD because of similarities between
alcoholic dementia and AD. Epidemiologic studies have investigated
the relationship between alcohol and AD, however, there is clear
indication that light to moderate alcohol intake (1–3 drinks per day;
b20 g alcohol per day) was signiﬁcantly associated with a lower risk
for AD (Anstey et al., 2009; Tyas, 2001). The neuroprotective effect of
antioxidant properties of wine polyphenols may be important in
preventing AD (Pinder and Sandler, 2004). Heavy drinking is a risk
factor for most stroke subtypes, while regular light to moderate
drinking seemed to be associated with a decreased risk for ischemic
strokes (Letenneur, 2004). It cannot be excluded that heavy drinking
may account for vascular damage in the brain and may contribute to
the development of AD .
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So far, the β-amyloid cascade is themost prominent hypothesis for
development of AD (Selkoe, 1998; Atwood et al., 2003; Tanzi et al.,
2004; Wirths et al., 2004; Marchesi, 2005; Schroeder and Koo, 2005)
and is thought to be the primary event that triggers the pathological
cascade in AD (Selkoe, 1998), although the ﬁndings in support of the
amyloid hypothesis have become questionable and controversial
(Robakis, 2010). The amyloid-precursor protein (APP) is cleaved by
secretases into β-amyloid peptides (40, 42, or 43 amino acids), and
these peptides aggregate under certain conditions and are deposited
as β-amyloid plaques. It is hypothesized that the accumulation of
β-amyloid in the brain causes the AD pathology and a dysbalance
between β-amyloid production and clearance results in other
hallmarks of the disease. The β-amyloid cascade hypothesis (Hardy
and Selkoe, 2002; Tanzi and Bertram, 2005) favors the model that
insoluble ﬁbrillar β-amyloid triggers the neuronal degeneration.
Evidence is now accumulating that soluble activated monomers,
soluble oligomers (dimer, trimer, tetramer), and protoﬁbrils could be
responsible for triggering the pathology in AD (Walsh et al., 2002;
Canevari et al., 2004). The exact mechanism by which β-amyloid
induces cell death is not known, but the “channel hypothesis”
suggests that certain ﬁbrillar forms of the peptide cause neurodegen-
eration by forming ion channels that are generally large, voltage
independent, and relatively poor selective (Wirths et al., 2004;
Marchesi, 2005). Soluble β-amyloid levels in the cortex correlate
with the degree of synaptic loss in dementia, and it becomesmore and
more clear that AD is primarily caused by dysfunction of nerve axons
and synapses (Selkoe, 2002). In AD, axonal degeneration may depend
on β-amyloid levels, but not on plaque deposition, which means that
nerve damage occurs before deposition of plaques.
β-amyloid is present in the brain and in the blood and is transported
through the BBB via two important receptor transport systems:
the receptor for advanced glycosylation end products (RAGE) and
low-density lipoprotein-related protein (LRP) (Tanzi et al., 2004;
Zlokovic, 2004). The inﬂux of β-amyloid from blood into brain is
mediated via RAGE,while the efﬂux frombrain into blood ismediated via
LRP(Tanzi et al., 2004; Zlokovic, 2004). This clearance frombrain toblood
is of pivotal importance for the regulation ofβ-amyloid levels in the brain
(Tanzi et al., 2004; Zlokovic, 2004) and a dysregulation of the BBB
contributes to enhanced β-amyloid levels in the brain. Under speciﬁc
conditions (highApoE4, lowpH,metals, anddysfunctional clearance) the
β-amyloid (1–42) peptide may aggregate in the brain.
A very high percentage (70%–90%) of AD patients show amyloid
pathology in their vessels, which narrow the vessels and produce
hypoperfusion (Smith and Greenberg, 2009; Farkas and Luiten, 2001;
Cullen et al., 2006; Hardy and Cullen, 2006). This cerebral amyloid
angiopathy can result in hemorrhagic and (possibly) ischemic forms
of stroke (Smith and Greenberg, 2009; Armstrong, 2006; Haglund
et al., 2006; Soffer, 2006; Boscolo et al., 2007). The cerebral amyloid
angiopathy is common in AD and is also associated with cerebral
atheriosclerosis (Farkas and Luiten, 2001; de la Torre, 2002; Attems
et al., 2004) andwith the development of cognitive deﬁcits (Thal et al.,
2003; Solfrizzi et al., 2004). As a consequence of cerebrovascular
dysfunction the breakdown of the BBBmay occur. This breakdownmay
have several effects on neurons, such as cell death after inﬂux of
excitotoxic amino acids (e.g. glutamate) or enhanced APP expression
after cholesterol inﬂux. In addition, an enhanced inﬂux of blood-derived
serum albumin into the brain is seen after BBB disrupture and may
induce neurodegeneration (Moser and Humpel, 2007).
5. Tauopathies, neurodegeneration, AD and vaD
Tau protein is a microtubule-associated protein that is highly
expressed in neurons in the brain. Tau is enriched in axons, where it
directly binds to microtubuli. In AD tau is hyperphosphorylated at avariety of serine and threonine residues and loses its ability to bind to
microtubuli. Such abnormal hyperphosphorylated tau is a major event
involved in the formation of paired helical neuroﬁbrillary tangles in
the AD brain (Mandelkow and Mandelkow, 1998; Spillantini and
Goedert, 1998; Smith et al., 2002; Iqbal et al., 2005). An imbalance
between protein kinases and phosphatases may play a role in
hyperphosphorylation. Interestingly, it has become apparent that
tau deposits are frequently observed in the abscence of amyloid
plaques, such as e.g. corticobasal degeneration, Pick disease or
progressive supranuclear palsy (Spillantini and Goedert, 1998).
Most taupathies are sporadic diseases but some are familial. These
ﬁndings suggest that neuroﬁbrillary tangles develop independent of
β-amyloid. Tau pathology in AD is almost entirely limited to nerve
cells, while in other tauopathies both nerve cells and glial cells are
affected (Spillantini and Goedert, 1998). In addition, enhanced tau is a
diagnostic marker in cerebrospinal ﬂuid for different forms of
neurodegeneration (e.g. Creutzfeldt Jacobs disease).
Iqbal et al. (2005) have developed the “Metabolic/Signal Transduc-
tion Hypothesis”. It is assumed that AD and other tauopathies require a
genetic predisposition (e.g. ApoE) and are triggered by a variety of
environmental (risk) factors (e.g. which alter themembrane ﬂuidity). It is
suggested that an imbalance of protein kinases (e,g, cdk5, glycogen
synthase kinase-3, CaM kinase II, protein kinase A) and/or phosphatases
(e.g. PP-2AorPP-1)may lead to anabnormalhyperphosphorylationof tau
and subsequently to formation of neuroﬁbrillary tangles in the brain.
There are indications that also vascular risk factor may play a role in tau
pathology, since e.g. a decreased membrane ﬂuidity by cholesterol could
be one event leading to an imbalance in this system. In addition a
decreased glucose metabolism/uptake might lead to the abnormal
hyperphosphorylation of tau through a decrease in its O-GlcNAcylation
(Iqbal et al., 2005). Finally, recently it has been shown that application of
truncated tau to the basolateral (brain) side of the BBB causes damage of
the BBB involving pro-inﬂammatory cytokines released from microglia
(Kovac et al., 2009).
6. The neurovascular unit, cholinergic neurons and NGF
The neurovascular unit (NVU) deﬁnes the cellular interaction
between brain capillary endothelial cells (forming the BBB), the
astrocytic end feet, and neuronal axons (Iadecola, 2004). Astrocytes
are involved in neuronal energy metabolism and synapse function
(Iadecola, 2004) and neuronal processes are closely associated with
cerebral blood vessels (Iadecola, 2004). Interestingly, nerve terminals
from the cholinergic neurons of the basal nucleus of Meynert interact
with astrocytic end feet of the BBB via muscarinic acetylcholine
receptors (Vaucher and Hamel, 1995; Farkas and Luiten, 2001). Thus
the NVU provides a direct link between the cerebrovascular system
and cholinergic neurons in the brain. Since the NVU provides the ﬁrst
line of defense against deleterious effects of cerebral ischemia and
other forms of injury (Iadecola, 2004), the NVU may display a very
sensitive (pH dependent) link to the brain. In fact, conditioned
medium collected from microvessels of AD patients has been shown
to kill neurons in vitro, pointing to selective neurotoxic factors
derived from brain capillary endothelial cells (Grammas et al., 1999).
This is in agreement with our own study, where we found that rat
primary capillary endothelial cells secreted factors into the medium,
which killed cholinergic neurons (Moser et al., 2004).
In AD a marked reduction of cholinergic neurons in the basal
forebrain (septum and nucleus basalis ofMeynert) is found in advanced
stages (Whitehouse et al., 1983;Wilcock et al., 1982),which leads to the
cholinergic hypothesis in AD (Francis et al., 1999; Humpel and Weis,
2002). Cholinergic cell loss directly correlateswith cognitivedecline and
a lack of acetylcholine is a hallmark in dementia and AD. It is not known,
why these cholinergic neurons die, but it seems possible that the direct
interaction with the cerebrovascular system may contribute to
cholinergic decline. In fact, damage of the NVU may result in
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cholinergic neurons. However, neurodegeneration in AD also results in
dysregulation of other neurotransmitter systems in the brain, such as
serotonine, noradrenaline, or glutamate.
Among all growth factors, nerve growth factor (NGF) is the most
potent growth factor to counteract cell death of cholinergic neurons in
vitro and in vivo (Thoenen and Barde, 1980; Levi-Montalcini, 1987). In
fact NGF was thought to play a role in the development of AD, but
transgenic NGF knockoutmice did not show anADpathology. However,
NGF was considered to be a candidate for treating AD and puriﬁed
mouse NGF was infused in some AD patients (Seiger et al., 1993).
Interestingly, NGF is upregulated in brains of AD patients (Fahnestock
et al., 2001) and in cerebrospinal ﬂuid (Hock et al., 2000), while the
high-afﬁnity NGF receptor trkA is downregulated (Mufson et al., 2002;
Counts et al., 2004). It can be explained that enhanced cortical
(target-derived)NGF is enhancedbut cannot be transported toneuronal
somata, because the axonal transport is destructed and the receptors are
not functional (Mufson et al., 1999). Recent evidence shows that the
precursor form of NGF (pro-NGF) and notmature NGF is liberated in the
brain, and its processing is regulated by plasmin, which is under control
of plasminogen activator (Bruno et al., 2009). In AD it has been
suggested that β-amyloid inducedmicroglial activationwould generate
oxidative stress (iNOS, peroxynitrite), which (1) inhibits processing of
pro-NGF to mature NGF and (2) activates matrix-metalloproteinase-9
and induces degradation of mature NGF. This event results in drastic
reduction of the bioactivity of NGF for the cholinergic neurons and may
further induce neuronal cell death (Bruno et al., 2009).
7. Silent strokes and acidosis
Cerebrovascular disease and ischemic brain injury secondary to
cardiovascular diseases are common causes of dementia and cognitive
decline in the elderly (Erkinjuntti et al., 2004). Territorial infarct, old
age, and low educational level were identiﬁed as predictors of
cognitive disorders after stroke (Rasquin et al., 2004). Stroke may
account for as many as 50% AD cases in old age (Kalaria, 2000), and it
is known that ischemic events induce APP, β-amyloid, and tau
pathology (Kalaria, 2000). Approximately 35% of AD patients show
autopsy-proven vascular infarcts and 60% show white matter lesions.
There exists an association between stroke and AD that may be due to
an underlying systemic vascular disease process or, alternatively, due
to the additive effects of stroke and AD pathologic features, leading to
an earlier age at onset of disease (Honig et al., 2003). Several
longitudinal studies report an association between stroke and
cognitive decline (Langa et al., 2004; Linden et al., 2004; Roman,
2004; Zhou et al., 2004). Such small ischemic lesions (“silent stroke”,
cortical microinfarcts; Kovari et al., 2007), which in isolation would
not alter cognition, substantially aggravate dementia, indicating that
cerebral ischemia may interact with AD pathology. It is now widely
accepted that acidosis is an important component of the pathological
event that leads to ischemic brain damage (Siesjo, 1988, 1992).
Acidosis is a result of either an increase in tissue CO2 or an
accumulation of acids produced by dysfunctional metabolism
(Rehncrona, 1985). Moderate ischemia may cause a fall in tissue pH
to around 6.6 without any morphological evidence of irreversible cell
damage (Rehncrona, 1985). In severe ischemia, anaerobic glycolysis
leads to accumulation of acids, for example, lactate, causing a decrease
in pH to around 6.0 (Rehncrona, 1985) with strong signs of
irreversible damage. We have recently shown that cholinergic
neurons undergo cell death when the pH is lowered to a critical
values of 6.8 (Pirchl et al., 2006). It is well known that acidosis
enhances iron-catalyzed production of reactive oxygen species,
probably by releasing iron from its binding to transferrin, ferritin, or
other proteins (Li and Siesjo, 1997). It seems likely that the NVU is
very sensitive for changes in pH and the interaction between vascular
structures and cholinergic nerve ﬁbers should be considered as acritical element in neurodegeneration, especially in the view of long-
standing suggestions that vessels are lost in the aging brain.
It is highly interesting to note that β-amyloid processing ismarkedly
affected by low pH, which could link acidosis to AD. Lactate caused a
dose-dependent increase in cellular β-amyloid immunoreactivity in
hippocampal neurons but acidosis did not affect secretion of sAPP
(Brewer, 1997). A marked Cu2+ induced aggregation of β-amyloid
emerged when the pH was lowered to 6.8, indicating that H+ induced
conformational changes unmask ametal-binding site onβ-amyloid that
mediates reversible assembly of the peptide that could have relevance
for plaque deposition in AD (Atwood et al., 1998). β-amyloid(15–22)
controls aggregation ofβ-amyloid(1–42) at acidic pH and its proteolytic
activity at neutral pH (Matsunaga et al., 1994). Prolonged acidosis may
in fact contribute to the dysregulation of β-amyloid and subsequent
plaque deposition and cell death of cholinergic neurons. We have
recently shown that under acidic conditions (pH 6.0+ApoE4)
cholinergic neurons degenerate in brain slices that is accompanied by
aggregated β-amyloid peptides (Marksteiner and Humpel, 2008).
8. Inﬂammation and the vascular connection in AD and vaD
Inﬂammation is an important trigger of neurodegeneration during
aging (“Inﬂammaging”) (Franceschi et al., 2000) and considered as a
major actor of neurodegeneration in AD. Inﬂammation is a potential
target for AD therapy and anti-inﬂammatory drugsmay delayAD (Perry
et al., 1995; Moore and O'Banion, 2002). In AD oxidation of DNA,
proteins and fatty acids occur in different brain areas. Some of the
oxidation products have been found in the neuroﬁbrillary tangles and
senile plaques (Markesbery and Carney, 1999) and these oxidative
modiﬁcations are closely associated with an inﬂammatory process in
the AD brain (Butterﬁeld et al., 2002). Indeed, cholinergic neurons of
the basal nucleus of Meynert are very sensitive for inﬂammatory insults
(Wenk et al., 2000, 2003). Chronic release of pro-inﬂammatory
cytokines, such as interleukin-1beta, tumor-necrosis-factor alpha
or transforming-growth factor-beta1, indicates a powerful role in
inﬂammation, pathology and neuronal dysfunction associated with
AD (Perry et al., 1995; Grammas and Ovase, 2002; Wenk et al., 2003).
These inﬂammatory processes include activation of microglia and
subsequent neuroinﬂammatory processes (Gonzalez-Scarano and
Baltuch, 1999). However, again it is not clear if inﬂammation is a result
of β-amyloid dysregulation (Moore and O'Banion, 2002) or if inﬂam-
mation itself is the primary cause in initiation of AD. Inﬂammation of
brain capillary endothelial cells may play a potent role, and it is well
known that endothelial cells strongly respond to inﬂammatory stimuli
(Moser et al., 2004) especially involving production of reactive oxygen
species (Iadecola, 2004).
9. Oxidative stress and mitochondrial failure in AD and vaD
A rapidly growing body of evidence indicates that increased oxidative
stress from reactive oxygen radicals is associated with increased
glutamate activity (Beal, 1996; Olanow, 1993; Coyle and Puttfarcken,
1993). Oxidative damage induced by free radicals targets intracellular
structures such as DNA, lipids, or proteins and these free radicals,
generated throughmitochondrialmetabolism, can act as causative factors
of abnormal function and cell death. These oxidative changes can arise
from the normal aging process, head trauma, silent strokes, increased
levels of heavy metals (iron, aluminum, and mercury), and possibly the
aggregation of β-amyloid (Aliev et al., 2003). Interestingly, in human
cerebral endothelial cells the endothelial barrier integrity is affected
through activation of glutamate NMDA receptors resulting in loss of the
cerebral endothelial barrier dysfunction (Sharp et al., 2003). In this
respect, glutamate is also known to promote a breakdownof the BBB (Del
Zoppo and Mabuchi, 2003). Some of the oxidation products have been
found in the neuroﬁbrillary tangles and senile plaques and these oxidative
modiﬁcations are closely associated with an inﬂammatory process in the
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generating the ATP for neurons, and a functional impairment results in
neurodegeneration. Interestingly, vascular hypoperfusion induces dys-
function of mitochondria in AD with subsequent RNA oxidation, lipid
peroxidation, or mitochondrial DNA deletion (Marcus et al., 1998;
Nunomura et al., 1999; Zhu et al., 2004).
10. Role of reactive astrocytes
It has been assumed that reactive astrocytes could contribute to the
pathomechanisms underlying AD by favoring oxidative neuronal damage
(Schubert et al., 2001).Microglial cytokines, such as e.g. interleukin-1beta
may, trigger production of apolipoprotein E and reactive astrocytes could
promote the transformation of beta-amyloid into toxic forms (Schubert
et al., 2001).Alternatively, it iswell established thatbeta-amyloidpeptides
causes striking changes in astrocytes by activating astroglial calcium
signaling (Abramov et al., 2004). These calcium signals were closely
associated with transient acidiﬁcation and generation of reactive oxygen
species (ROS) and itwas assumed that oxidative stress induced in reactive
astrocytes may contribute to neuronal cell death (Abramov et al., 2004).
Interestingly, it has been shown that astrocytic nitric oxide triggers
hyperphosphorylation in hippocampal neurons (Saez et al., 2004).
11. A common hypothesis — what is the link?
Howdoall these puzzle stonesﬁt into onemodel? It is not clear, how
AD is caused and it is not clear how the different forms of dementia ﬁtFig. 1. A common unifying hypothesis for Alzheimer's disease. It is hypothesized that chronic
Alzheimers disease. These factors are e.g. hyperhomocysteinemia, hypercholesterolemia or
silent strokes and acidic conditions (1) or to a dysregulation of β-amyloid at the blood
cerebrovascular dysfunction may result in a damage of the sensitive neurovascular unit (3). T
lack of cortical or hippocampal acetylcholine (4). Metabolic disturbances (e.g. enhanced inﬂ
may induce neuroinﬂammation (5) and microglial activation and reactive gliosis (6). Dif
β-amyloid) may result in aggregation of beta-amyloid and plaque deposition (7). The ce
β-amyloid (angiopathy) in brain vessels (8). It is suggested that metabolic disturbances c
abnormal tau phosphorylation, which ﬁnally cause the tau pathology (9). Microglia inﬂam
metabolism of nerve growth factor (NGF) with a reduced bioavailability for cholinergic neuro
by β-amyloid plaque deposition (11) or may contribute to neuronal cell death (12).into one model. Is vascular dementia another disease or is it an early
stage of AD? Ismild cognitive impairment the earliest form of AD and of
vascular dementia? Many researchers favor the β-amyloid cascade
hypothesis, and think that a dysregulation of β-amyloid metabolism is
the primary cause for AD. Other researchers believe that only tau may
account for the disease without affecting the β-amyloid processing.
Putting several evidence together, it seems possible that the aging of the
cerebrovascular system may trigger the development of dementia: age
is the most important risk factor and different vascular risk factors
correlatewith the development of dementia andwith cognitive deﬁcits.
So far there is evidence that AD could be caused by two initial
events (Fig. 1): chronic mild exposure to (cardiovascular) risk factors
over years causes (1) damage of the brain cerebrovascular system
leading to metabolic disturbances in the brain or (2) a dysbalance of
the clearance of β-amyloid from brain to blood or vice versa which
may increase brain β-amyloid levels. A cascade of downstream events
may lead to β-amyloid plaques and tau pathology. The risk factors
may include e.g. hyperhomocysteinemia, hypercholesterolemia, type
2 diabetes or likely combinations.
Pathway 1 (vascular): It is suggested that a vascular damage results
in silent strokes and acidic conditions leading to several metabolic
disturbances, such as enhanced inﬂux of toxic compounds, or decreased
efﬂux of metabolic waste and reduced energy supply (Fig. 1). In parallel
a damage of the sensitive NVU may occur. As a result of the damage of
the NVU cholinergic synapses lose contact with the NVU. It seems likely
that such an event may cause retrograde-induced axonal damage and
subsequent cell death of cholinergic neurons (Fig. 1). Such a loss ofmild exposure of different (vascular) risk factors may play a role in the development of
type 2 diabetes. This leads to damage of the neurovascular brain capillaries leading to
-brain barrier resulting in increased β-amyloid (1–42) levels in the brain (2). The
he subsequent retrograde-induced cell death of cholinergic neurons correlates with the
ux of toxic compounds, reduced efﬂux of metabolic waste, or reduced energy supply)
ferent risk factors (such as metals, reduced pH, reduced transport or degradation of
rebrovascular damage and dysfunctional β-amyloid clearance result in deposition of
ause an imbalance of speciﬁc protein kinases (PK) or phosphatases (PP), resulting in
mation enhances matrix metalloproteinase-9 (MMP9) and cause a dysfunction of the
ns, supporting their cell death (10). Tau pathologymay on the other hand also be caused
230 C. Humpel / Experimental Gerontology 46 (2011) 225–232cholinergic neurons correlates with lack of acetylcholine in cortex and
hippocampus, resulting in retrograde cell death of cholinergic neurons
(Fig. 1). The resulting microglial activation causes release of proinﬂam-
matory cytokines and oxdiative stress with production of radicals and
ﬁnally reactive gliosis. It has been shown that this results in enhanced
degradation of NGF and thus a decrease of NGF bioavailability for
cholinergic neurons further induces neurodegeneration of cholinergic
neurons.
Pathway 2 (clearance): Yet unknown risk factors may damage the
BBB and result in dysfunctional clearance of β-amyloid from brain to
blood. Alternatively, peripheral blood-derived β-amyloid enters the
brain (Fig. 1). Such a dysfunctional clearance may result in enhanced
β-amyloid levels in the brain tissue (Fig. 1). Different risk factors, such
as metals (copper, zink), reduced pH (b6.8), dysfunctional transport
or degradation of β-amyloid induce aggregation of β-amyloid
resulting in plaque deposition (Fig. 1). As a cause of either vascular
damage and/or β-amyloid dysfunctional clearance, deposition of
β-amyloid in vessels (angiopathy) may occur (Fig. 1).
Pathway 3 (Tau pathology). It is suggested that the metabolic
disturbances cause an imbalance of speciﬁc protein kinases and
phosphatases. This dysregulation causes abnormal tau phosphorylation
and ﬁnally formation of paired helical ﬁlaments, the typical tau
pathology. The abnormal tau pathology may further contribute to
cholinergic cell death. It is not fully clear if β-amyloid plaques may
directly induce tau pathology.
It seems possible that the different stages in dementia are deﬁned
as the extent of damage of the cerebrovascular system and all
subsequent events in the brain. However, it cannot be excluded that
the “ﬁnal link” is still missing, whichmay favor another, or a modiﬁed,
hypothesis. Recently, it has been proposed that the blood-clotting
factor ﬁbrinogen could be one of the “missing links” of vascular and
AD pathologies (Cortes-Canteli et al., 2010; Wood, 2010).
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